Several genomic‐based assays, including the Oncotype DX assay,8 MammaPrint,9 and PAM50,10 have been devised to predict responses to adjuvant therapy and the risk of distant recurrence in early‐stage hormone receptor (HR)‐positive breast cancer patients. Here, NR4A1 is linked to breast cancer.